These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 28838713)

  • 1. Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non-Small Cell Lung Cancer Treated with Nivolumab.
    Funazo T; Nomizo T; Kim YH
    J Thorac Oncol; 2017 Sep; 12(9):e140-e141. PubMed ID: 28838713
    [No Abstract]   [Full Text] [Related]  

  • 2. Nivolumab (Opdivo°) and metastatic or inoperable lung cancer.
    Prescrire Int; 2017 Apr; 26(181):93-94. PubMed ID: 30730658
    [No Abstract]   [Full Text] [Related]  

  • 3. Nivolumab improves survival for patients with advanced lung cancer.
    Printz C
    Cancer; 2017 Sep; 123(17):3211. PubMed ID: 28833027
    [No Abstract]   [Full Text] [Related]  

  • 4. Neutrophil-to-lymphocyte ratio after four weeks of nivolumab administration as a predictive marker in patients with pretreated non-small-cell lung cancer.
    Takeda T; Takeuchi M; Saitoh M; Takeda S
    Thorac Cancer; 2018 Oct; 9(10):1291-1299. PubMed ID: 30126063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer.
    Komatsu T; Nakamura K; Kawase A
    J Thorac Oncol; 2017 Sep; 12(9):e143-e144. PubMed ID: 28838715
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical impact of post-progression survival on overall survival in patients receiving nivolumab monotherapy as a second-line treatment for advanced non-small cell lung cancer.
    Imai H; Yamaguchi O; Mori K; Hashimoto K; Akagami T; Shinomiya S; Miura Y; Shiono A; Mouri A; Kaira K; Kobayashi K; Kagamu H
    Thorac Cancer; 2021 Apr; 12(8):1171-1179. PubMed ID: 33626218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive Performance of Four Programmed Cell Death Ligand 1 Assay Systems on Nivolumab Response in Previously Treated Patients with Non-Small Cell Lung Cancer.
    Fujimoto D; Sato Y; Uehara K; Ishida K; Fukuoka J; Morimoto T; Kawachi H; Mori R; Ito M; Teraoka S; Nagata K; Nakagawa A; Otsuka K; Imai Y; Tomii K
    J Thorac Oncol; 2018 Mar; 13(3):377-386. PubMed ID: 29233789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-lasting responses after discontinuation of nivolumab treatment for reasons other than tumor progression in patients with previously treated, advanced non-small cell lung cancer.
    Kimura H; Araya T; Yoneda T; Shirasaki H; Kurokawa K; Sakai T; Koba H; Tambo Y; Nishikawa S; Sone T; Kasahara K
    Cancer Commun (Lond); 2019 Nov; 39(1):78. PubMed ID: 31753015
    [No Abstract]   [Full Text] [Related]  

  • 9. Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients.
    Sarocchi M; Grossi F; Arboscello E; Bellodi A; Genova C; Dal Bello MG; Rijavec E; Barletta G; Rossi G; Biello F; Ghigliotti G; Canepa M; Mussap M; Brunelli C; Spallarossa P
    Oncologist; 2018 Aug; 23(8):936-942. PubMed ID: 29567824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparable outcomes of nivolumab in patients with advanced NSCLC presenting with or without brain metastases: a retrospective cohort study.
    Zhang G; Cheng R; Wang H; Zhang Y; Yan X; Li P; Zhang M; Zhang X; Yang J; Niu Y; Ma Z
    Cancer Immunol Immunother; 2020 Mar; 69(3):399-405. PubMed ID: 31907567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive factors for progression-free survival in non-small cell lung cancer patients receiving nivolumab based on performance status.
    Adachi Y; Tamiya A; Taniguchi Y; Enomoto T; Azuma K; Kouno S; Inagaki Y; Saijo N; Okishio K; Atagi S
    Cancer Med; 2020 Feb; 9(4):1383-1391. PubMed ID: 31880861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastases.
    Kitadai R; Okuma Y; Hakozaki T; Hosomi Y
    J Cancer Res Clin Oncol; 2020 Mar; 146(3):777-785. PubMed ID: 31828427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety.
    Hida T
    Ther Adv Respir Dis; 2018; 12():1753466618801167. PubMed ID: 30249170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early Use of Systemic Corticosteroids in Patients with Advanced NSCLC Treated with Nivolumab.
    Scott SC; Pennell NA
    J Thorac Oncol; 2018 Nov; 13(11):1771-1775. PubMed ID: 29935305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developing a Predictive Model for Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients Treated With Nivolumab.
    Park W; Kwon D; Saravia D; Desai A; Vargas F; El Dinali M; Warsch J; Elias R; Chae YK; Kim DW; Warsch S; Ishkanian A; Ikpeazu C; Mudad R; Lopes G; Jahanzeb M
    Clin Lung Cancer; 2018 May; 19(3):280-288.e4. PubMed ID: 29336998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful continuous nivolumab therapy for metastatic non-small cell lung cancer after local treatment of oligometastatic lesions.
    Tobita S; Kinehara Y; Tamura Y; Kurebe H; Ninomiya R; Utsu Y; Kohmo S; Sato B; Nagai K; Maruoka S; Jokoji R; Koyama S; Tachibana I
    Thorac Cancer; 2020 Aug; 11(8):2357-2360. PubMed ID: 32567218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperprogressive disease in patients with non-small cell lung cancer treated with nivolumab: A case series.
    Kanazu M; Edahiro R; Krebe H; Nishida K; Ishijima M; Uenami T; Akazawa Y; Yano Y; Yamaguchi T; Mori M
    Thorac Cancer; 2018 Dec; 9(12):1782-1787. PubMed ID: 30328672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab.
    Khunger M; Velcheti V
    J Thorac Oncol; 2017 Jul; 12(7):e96-e97. PubMed ID: 28629548
    [No Abstract]   [Full Text] [Related]  

  • 19. Real-world Efficacy and Safety of Nivolumab for Advanced Non-Small-cell Lung Cancer: A Retrospective Multicenter Analysis.
    Kobayashi K; Nakachi I; Naoki K; Satomi R; Nakamura M; Inoue T; Tateno H; Sakamaki F; Sayama K; Terashima T; Koh H; Abe T; Nishino M; Arai D; Yasuda H; Kawada I; Soejima K; Betsuyaku T;
    Clin Lung Cancer; 2018 May; 19(3):e349-e358. PubMed ID: 29398578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Systemic Corticosteroid Therapy on the Efficacy and Safety of Nivolumab in the Treatment of Non-Small-Cell Lung Cancer.
    Umehara K; Yama K; Goto K; Wakamoto A; Hatsuyama T; Honjo O; Saikai T; Fujita A; Sato H
    Cancer Control; 2021; 28():1073274820985790. PubMed ID: 33733906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.